Minnesota Oncology

Hodgkin's Lymphoma News

Rituxan Active in Nodular Lymphocyte-Predominant Hodgkin’s Lymphoma (February 26, 2014)

Rituxan® (rituximab) was active in previously treated and untreated patients with nodular lymphocyte–predominant Hodgkin lymphoma, according to the results of a phase II study published in the Journal of Clinical Oncology. Most patients relapsed,... Continue Reading

Adcetris and PET-Adapted Salvage Therapy Effective in Relapsed/Refractory Hodgkin’s Lymphoma (January 16, 2014)

Patients with relapsed/refractory Hodgkin’s lymphoma who achieve complete responses after treatment with Adcetris® (brentuximab vedotin) can skip more toxic salvage therapy and proceed straight to transplant, according to the results of a study presented... Continue Reading

End-of-Life Care Remains Aggressive, Despite Patient Wishes (September 16, 2013)

Although most patients with advanced cancer prefer hospice or palliative care that minimizes symptoms, many continue to receive aggressive treatment during their final weeks and months of life. In fact, elderly patients with advanced cancer often receive... Continue Reading

Following Lifestyle Recommendations Reduces Risk of Cancer Death (May 15, 2013)

People who follow the diet and lifestyle recommendations laid out by the World Cancer Research Fund (WCRF) and the American Institute for Cancer Research (AICR) have a 34 percent reduced risk of dying from several diseases and specifically, a 20 percent... Continue Reading

Cancer Deaths on the Decline (February 11, 2013)

Overall cancer death rates continue to decline in both men and women and across major ethnic and racial groups, according to the annual Status of Cancer report published in the Journal of the National Cancer Institute. What’s more—cancer incidence... Continue Reading

Adcetris Improves Response Rates to ABVD in Hodgkin’s Lymphoma (January 2, 2013)

Adding Adcetris® (brentuximab vedotin) to the chemotherapy regimen ABVD produces a high complete response rate with a moderate increase in toxicity in patients with advanced Hodgkin’s lymphoma, according to the results of a study presented at the 19th... Continue Reading

Children with Favorable-Risk Hodgkin’s Lymphoma May Benefit from Limited Radiation Therapy (July 6, 2012)

Children with favorable-risk Hodgkin’s lymphoma who achieve a complete early response to chemotherapy may not require radiation therapy or may undergo limited radiation therapy, according to the results of a study published in the Journal of the American... Continue Reading

Approximately 16% of Worldwide Cancers Caused By Preventable Infections (May 17, 2012)

Two million cancer cases each year—or roughly 16 percent of cancers worldwide—are the result of preventable and treatable infections such as human papillomavirus (HPV) and Hepatitis C (HCV), according to the results of a study published in The Lancet... Continue Reading

Aspirin Continues to Look Promising for Cancer Prevention (March 26, 2012)

A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce... Continue Reading

Lymphoma During Pregnancy Can Have Good Outcomes (March 14, 2012)

Among women who are diagnosed with lymphoma during pregnancy, the outcomes for both mother and baby are often good. This was true for women who began lymphoma treatment during the second or third trimester of pregnancy, as well as women who deferred treatment... Continue Reading

Latest Hodgkin's Lymphoma News By Stage


Advanced Stage Hodgkin's Lymphoma

Rituxan Active in Nodular Lymphocyte-Predominant Hodgkin’s Lymphoma (February 26, 2014)

Rituxan® (rituximab) was active in previously treated and untreated patients with nodular lymphocyte–predominant Hodgkin lymphoma, according to the results of a phase II study published in the Journal of Clinical Oncology. Most patients relapsed,... Continue Reading

Adcetris and PET-Adapted Salvage Therapy Effective in Relapsed/Refractory Hodgkin’s Lymphoma (January 16, 2014)

Patients with relapsed/refractory Hodgkin’s lymphoma who achieve complete responses after treatment with Adcetris® (brentuximab vedotin) can skip more toxic salvage therapy and proceed straight to transplant, according to the results of a study presented... Continue Reading

Adcetris Improves Response Rates to ABVD in Hodgkin’s Lymphoma (January 2, 2013)

Adding Adcetris® (brentuximab vedotin) to the chemotherapy regimen ABVD produces a high complete response rate with a moderate increase in toxicity in patients with advanced Hodgkin’s lymphoma, according to the results of a study presented at the 19th... Continue Reading

Lymphoma During Pregnancy Can Have Good Outcomes (March 14, 2012)

Among women who are diagnosed with lymphoma during pregnancy, the outcomes for both mother and baby are often good. This was true for women who began lymphoma treatment during the second or third trimester of pregnancy, as well as women who deferred treatment... Continue Reading

Similar Overall Survival with ABVD and BEACOPP for Advanced Hodgkin’s Lymphoma (July 25, 2011)

Although the BEACOPP chemotherapy regimen produces better initial tumor control than the commonly used and less toxic ABVD regimen, the two regimens produce similar overall survival among patients with advanced Hodgkin’s lymphoma. These results were... Continue Reading

More Advanced Stage Hodgkin's Lymphoma

Early Stage Hodgkin's Lymphoma

Rituxan Active in Nodular Lymphocyte-Predominant Hodgkin’s Lymphoma (February 26, 2014)

Rituxan® (rituximab) was active in previously treated and untreated patients with nodular lymphocyte–predominant Hodgkin lymphoma, according to the results of a phase II study published in the Journal of Clinical Oncology. Most patients relapsed,... Continue Reading

Children with Favorable-Risk Hodgkin’s Lymphoma May Benefit from Limited Radiation Therapy (July 6, 2012)

Children with favorable-risk Hodgkin’s lymphoma who achieve a complete early response to chemotherapy may not require radiation therapy or may undergo limited radiation therapy, according to the results of a study published in the Journal of the American... Continue Reading

Lymphoma During Pregnancy Can Have Good Outcomes (March 14, 2012)

Among women who are diagnosed with lymphoma during pregnancy, the outcomes for both mother and baby are often good. This was true for women who began lymphoma treatment during the second or third trimester of pregnancy, as well as women who deferred treatment... Continue Reading

Limited Therapy May Cure a Significant Fraction of Pediatric Patients with Early-Stage Hodgkin Lymphoma (June 13, 2011)

At the 2011 meeting of the American Society of Clinical Oncology, researchers involved in the Pediatric Oncology Study Group (POG) reported that selected pediatric patients with stage I and II Hodgkin lymphoma could be cured without alkylating agent chemotherapy... Continue Reading

Many Patients with “Chemo Brain” Recover within Five Years (May 23, 2011)

A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients. For some patients, however, symptoms may persist... Continue Reading

More Early Stage Hodgkin's Lymphoma

Progressive Relapsed Hodgkin's Lymphoma

Adcetris and PET-Adapted Salvage Therapy Effective in Relapsed/Refractory Hodgkin’s Lymphoma (January 16, 2014)

Patients with relapsed/refractory Hodgkin’s lymphoma who achieve complete responses after treatment with Adcetris® (brentuximab vedotin) can skip more toxic salvage therapy and proceed straight to transplant, according to the results of a study presented... Continue Reading

Adcetris Improves Response Rates to ABVD in Hodgkin’s Lymphoma (January 2, 2013)

Adding Adcetris® (brentuximab vedotin) to the chemotherapy regimen ABVD produces a high complete response rate with a moderate increase in toxicity in patients with advanced Hodgkin’s lymphoma, according to the results of a study presented at the 19th... Continue Reading

Adcetris Approved for Two Types of Lymphoma (August 26, 2011)

The targeted therapy Adcetris™ (brentuximab vedotin) has received accelerated approved by the US Food and Drug Administration (FDA) for the treatment of two types of lymphoma: Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL). Hodgkin... Continue Reading

Many Patients with “Chemo Brain” Recover within Five Years (May 23, 2011)

A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients. For some patients, however, symptoms may persist... Continue Reading

Targeted Therapy Promising for Relapsed Hodgkin Lymphoma (January 12, 2011)

In a Phase II clinical trial, three-quarters of patients with relapsed or refractory Hodgkin lymphoma responded to treatment with the investigational drug brentuximab vedotin. These results were presented at the 2010 annual meeting of the American Society... Continue Reading

More Progressive Relapsed Hodgkin's Lymphoma